Patient characteristics
Parameters . | No. of patients (%) . |
|---|---|
| Total no. | 204 (100) |
| Sex | |
| Male | 116 (57) |
| Female | 88 (43) |
| Age, y | |
| Median | 68 |
| Range | 43-89 |
| Rai stage | |
| Low, 0 | 63 (31) |
| Intermediate, 1-2 | 98 (48) |
| High, 3-4 | 34 (17) |
| Unknown | 9 (4) |
| Disease activity | |
| Stable | 101 (50) |
| Progressive | 68 (33) |
| Unknown | 35 (17) |
| Previous therapy | |
| Chemonaive | 138 (68) |
| Treatment ended more than 4 wks before | 57 (28) |
| Under treatment | 9 (4) |
| Molecular risk parameters | |
| Zap-70+ B-CLL cells, at least 20% | 90 (44) |
| Unmutated Ig VH gene* | 48 (37) |
| Unfavorable genetic aberration(s), del17p, 11q, 12+* | 42 (30) |
Parameters . | No. of patients (%) . |
|---|---|
| Total no. | 204 (100) |
| Sex | |
| Male | 116 (57) |
| Female | 88 (43) |
| Age, y | |
| Median | 68 |
| Range | 43-89 |
| Rai stage | |
| Low, 0 | 63 (31) |
| Intermediate, 1-2 | 98 (48) |
| High, 3-4 | 34 (17) |
| Unknown | 9 (4) |
| Disease activity | |
| Stable | 101 (50) |
| Progressive | 68 (33) |
| Unknown | 35 (17) |
| Previous therapy | |
| Chemonaive | 138 (68) |
| Treatment ended more than 4 wks before | 57 (28) |
| Under treatment | 9 (4) |
| Molecular risk parameters | |
| Zap-70+ B-CLL cells, at least 20% | 90 (44) |
| Unmutated Ig VH gene* | 48 (37) |
| Unfavorable genetic aberration(s), del17p, 11q, 12+* | 42 (30) |
The indicated risk parameters were available for a subgroup of patients: Ig VH mutational status (n = 130) and genomic aberrations (n = 140). Statistical analyses for differences in tumor load, clinical stage, sex, disease activity, and treatment-free survival revealed no significant differences between subgroups and the total patients' cohort (data not shown), ruling out that results are biased by patient selection.